Burning Mouth Syndrome and Salivary Brain Derived Neurotrophic Factor Level in Type 2 Diabetes Mellitus Patients on Metformin Monotherapy and on Combination of Metformin and Glibenclamide (A Comparative Study)

Authors

  • Suhair A. Hussain1 , Enas F. Kadhim2

DOI:

https://doi.org/10.37506/ijfmt.v14i2.10552

Keywords:

Burning mouth syndrome, metformin, glibenclamide, salivary brain derived neurotrophic factor, Diabetes Mellitus

Abstract

Background: Diabetes mellitus is a chronic, progressive, incompletely understood metabolic condition
chiefly characterized by hyperglycemia. Impaired insulin secretion, resistance to tissue actions of insulin, or
a combination of both are thought to be the commonest reasons contributing to the pathophysiology of type
2 diabetes mellitus.
Objectives: The objectives of this study were to estimate the salivary Brain Derived Neurotrophic Factor
level in type 2 diabetes mellitus patients on treatment of metformin as a monotherapy and those on
combination treatment of metformin and glibenclamide. Also to evaluate the burning mouth syndrome in
patients with diabetes mellitus under hypoglycemic agents.
Method: In this study 80 male subjects divided into 3 groups: Group 1: 30 subjects as healthy control
group, Group 2: 25 subjects with type 2 diabetes under treatment of metformin as a monotherapy 500
mg twice/day and duration 12- 18 months, and Group 3: 25 subjects with type 2 diabetes treated with
combination of metformin 500 mg twice/day and glibenclamide 5mg twice/day and duration 12- 18 months.
Oral examination was done for each participant and the oral manifestations were recorded. Unstimulated
whole saliva samples were collected to measure the brain derived neurotrophic factor level and comparing
the results with each group. Body mass index for all participants was recorded. Salivary Brain derived
neurotrophic factor concentrations were measured by enzyme linked immunosorbent assay ELIZA.
Results: The results showed that the burning mouth syndrome was seen in both patients groups. Statistical
analysis showed a significant increase in burning mouth syndrome among the study groups. Regarding
salivary brain derived neurotrophic factor, results revealed that there was a significant higher in combination
group as compared to control and metformin monotherapy group.
Conclusion: Both monotherapy and combination therapy was affect salivary level of brain derived
neurotrophic factor. Burning mouth syndrome was seen secondarily to diabetes and poor glycemic control
and seen in both patients groups.

Author Biography

  • Suhair A. Hussain1 , Enas F. Kadhim2

    1M.Sc.student, 2Assistant professor, Department of Oral Diagnosis, Collage of Dentistry, University of Baghdad

Downloads

Published

2020-04-29

How to Cite

Burning Mouth Syndrome and Salivary Brain Derived Neurotrophic Factor Level in Type 2 Diabetes Mellitus Patients on Metformin Monotherapy and on Combination of Metformin and Glibenclamide (A Comparative Study). (2020). Indian Journal of Forensic Medicine & Toxicology, 14(2), 2106-2112. https://doi.org/10.37506/ijfmt.v14i2.10552